| http://www.w3.org/ns/prov#value | - We are developing CG400549 to target resistant bacterial strains such as MRSA and Vancomycin Resistant Staphylococcus aureus (VRSA) and recently initiated a phase II clinical study in the US after successfully completing two phase I studies in the EU. Although we do not have human efficacy data yet, CG400549 has displayed remarkable in-vitro and in-vivo efficacy against some of the gold standard
|
